Abstract
Aim
G-protein coupled receptor agonists are currently under investigation for their potential utility in patients with type 2 diabetes mellitus (T2DM). The objective was to determine the pharmacokinetics, pharmacodynamics, safety and tolerability of GPR119 agonist, JNJ-38431055 in T2DM subjects.Methods
This was a randomized, double-blind, placebo- and positive-controled, single-dose cross-over study and a randomized, double-blind, placebo-controled multiple-dose parallel design study. The study was conducted at 4 US research centres. Two different experiments involving 25 and 32 different subjects were performed in male and female subjects, aged 25-60 years, mean body mass index between 22 and 39.9 kg/m2 who had T2DM diagnosed 6 months to 10 years before screening. JNJ-38431055 (100 and 500 mg) or sitagliptin (100 mg) as a single-dose or JNJ-38431055 (500 mg) once daily for 14 consecutive days were tested. Effects on stimulated plasma glucose, insulin, C-peptide and incretin concentrations were pre-specified outcomes.Results
JNJ-38431055 was well tolerated and not associated with hypoglycaemia. Plasma systemic exposure of JNJ-38431055 increased as the dose increased, was approximately two-fold greater after multiple-dose administration, and attained steady-state after approximately 8 days. Compared with placebo, single-dose administration of oral JNJ-38431055 decreased glucose excursion during an oral glucose tolerance test, but multiple-dose administration did not alter 24-h weighted mean glucose. Multiple dosing of JNJ-38431055 increased post-meal total glucagon-like peptide 1 and gastric insulinotropic peptide concentrations compared to baseline.Conclusions
These studies provide evidence of limited glucose lowering and incretin activity for JNJ-38431055 in subjects with T2DM.References
Articles referenced by this article (26)
A gut feeling for obesity: 7TM sensors on enteroendocrine cells.
Cell Metab, (6):447-449 2008
MED: 19041758
Receptors for acylethanolamides-GPR55 and GPR119.
Prostaglandins Other Lipid Mediat, (3-4):105-111 2009
MED: 19615459
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes.
Nat Rev Drug Discov, (5):369-385 2009
MED: 19365392
GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity.
Br J Pharmacol, S76-81 2007
MED: 18037923
G protein-coupled receptors and insulin secretion: 119 and counting.
Endocrinology, (6):2598-2600 2007
MED: 17507578
A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.
Endocrinology, (5):2038-2047 2008
MED: 18202141
GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell.
Diabetes, (5):1058-1066 2009
MED: 19208912
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Lancet, (9548):1696-1705 2006
MED: 17098089
Show 10 more references (10 of 26)
Citations & impact
Impact metrics
Article citations
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy.
Endocr Rev, 43(3):507-557, 01 May 2022
Cited by: 23 articles | PMID: 35552683 | PMCID: PMC9113190
Review Free full text in Europe PMC
Targeting the Enteroendocrine System for Treatment of Obesity.
Handb Exp Pharmacol, 274:487-513, 01 Jan 2022
Cited by: 0 articles | PMID: 35419620
Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.
Cell Mol Biol Lett, 26(1):32, 07 Jul 2021
Cited by: 13 articles | PMID: 34233623 | PMCID: PMC8265056
Review Free full text in Europe PMC
Nutrient-Induced Cellular Mechanisms of Gut Hormone Secretion.
Nutrients, 13(3):883, 09 Mar 2021
Cited by: 22 articles | PMID: 33803183 | PMCID: PMC8000029
Review Free full text in Europe PMC
Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges.
Nat Rev Endocrinol, 17(3):162-175, 25 Jan 2021
Cited by: 35 articles | PMID: 33495605
Review
Go to all (58) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Clin Ther, 28(1):55-72, 01 Jan 2006
Cited by: 169 articles | PMID: 16490580
Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes.
J Clin Endocrinol Metab, 91(11):4612-4619, 15 Aug 2006
Cited by: 329 articles | PMID: 16912128
Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Clin Ther, 32(6):1188-1204, 01 Jun 2010
Cited by: 34 articles | PMID: 20637971
Sitagliptin: a novel drug for the treatment of type 2 diabetes.
Cardiol Rev, 15(5):264-271, 01 Sep 2007
Cited by: 22 articles | PMID: 17700385
Review
Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Cleve Clin J Med, 76 Suppl 5:S12-9, 01 Dec 2009
Cited by: 34 articles | PMID: 19952298
Review